Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation.

Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer.

Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels.

Pneumonitis Rates Before and After Adoption of Immunotherapy Consolidation in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiation.

Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors.

Attributed Graph Force Learning.

Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC.

Brief Report: Long-Term Follow-Up of Adjuvant Pembrolizumab After Locally Ablative Therapy for Oligometastatic NSCLC.

Severe disease during both primary and secondary dengue virus infections in pediatric populations.

Concurrent Circulating Tumor DNA and Tissue Genotyping-Ready for Prime Time?

The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC.

Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression.

PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer.

Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors.

Functional and transcriptional heterogeneity within the massively expanding HLADR(+)CD38(+) CD8 T cell population in acute febrile dengue patients.